Nanotechnology Now - Press Release: Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

Home > Press > Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

Abstract:
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc. The company's common stock will continue to trade on the NASDAQ Global Select Market under the existing stock ticker symbol, ARWR. These shares have been assigned a new CUSIP number of 04280A100. Holders of stock certificates with the prior corporate name, need not take any action.

Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

Pasadena. CA | Posted on April 6th, 2016

As part of this name change, the company has also launched a new corporate website at www.arrowheadpharma.com and a new Twitter handle @ArrowheadPharma.

Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals, said: "Now is the time to acknowledge that our key priorities are increasingly focused on advancing products through clinical development to bring innovative new medicines to patients. The name Arrowhead Pharmaceuticals is more consistent with our stage of development as a company and reflects the great progress we're making on our broad pipeline of RNAi-based drugs."

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.

For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit

ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com